Boston Scientific (BSX) Misses Q3 EPS by 1c

Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.43, $0.01 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $3.17 billion versus the consensus estimate of $3.15 billion.

GUIDANCE:

Boston Scientific sees Q4 2022 EPS of $0.45-$0.48, versus the consensus of $0.49.

Boston Scientific sees FY2022 EPS of $1.71-$1.74, versus the consensus of $1.76.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• AXIL Brands (AXIL) Tops Q4 EPS by 4c
• Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance